AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 453775
Drug: Methyldopa (MD)
RxNorm normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methyldopa (MD) 250 mg t.i.d.
Trial: 453775
Drug: Prazosin (Pz)
DrugBank: Prazosin (DB00457)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prazosin (Pz) + Diuretic
Trial: 27640922
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose shockwave therapy
Trial: 20471117
Drug: No statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No statin treatment before PCI (control group)
Trial: 17260161
Drug: Induction of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction of hyperammonemia by administration of a solution mimicking the amino acid composition of haemoglobin (60)
Trial: 14696754
Drug: 30 or
RxNorm normalized name: Oseni 25/30 Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 or 60 mg folic acid with or without vitamins B6 and B12 for eight weeks
Trial: 14696754
Drug: Intravenous folinic
RxNorm normalized name: oxolinic acid
DrugBank: Oxolinic acid (DB13627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous folinic acid given alone or with serine for eight weeks
Trial: 9191629
Drug: Educational materials
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational materials (medication booklet, behavioral health booklet, video)
Trial: 28384657
Drug: Metronomic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronomic chemotherapy (4-drug oral regimen: daily celecoxib and thalidomide with alternating periods of etoposide and cyclophosphamide)
Trial: 28384657
Drug: Metronomic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronomic chemotherapy (4-drug oral regimen)
Trial: 19556076
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further treatment (Group B)
Trial: 16478755
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg l-dopa
Trial: 9771303
Drug: Intravenous atropine
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous atropine 0.02 mg kg‐1 (Group A, n = 25)
Trial: 9771303
Drug: Glycopyrrolate 0.004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate 0.004 mg kg‐1 (Group G, n = 27)
Trial: 7834593
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of four sessions in the clinic, four sessions in real-life, and six follow-up sessions in the clinic
Trial: 3401658
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g ampicillin and 80 mg gentamicin pre‐operatively
Trial: 29263079
Drug: Real-time therapeutic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Real-time therapeutic drug monitoring (TDM) with same-day real-time dose adaptation
Trial: 26654125
Drug: Oral nutrition
RxNorm normalized name: BAGS/TUBES/SUPPLIES FOR ORAL NUTRITION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutrition supplement (ONS)
Trial: 23047542
Drug: Preprandial insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preprandial insulin aspart (Asp)
Trial: 23047542
Drug: Postprandial insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postprandial insulin glulisine (Glu)
Trial: 16967595
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid and dipyridamole (30‐325 mg daily and 200 mg twice daily)
Trial: 16967595
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid only (30‐325 mg daily)
Trial: 15518751
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) at doses of 0.5, 1, 1.5, and 2 g/day
Trial: 7683447
Drug: 500 ml
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml hydroxyethyl starch (HAES)
Trial: 7683447
Drug: 500 ml
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml NaCl 0.9%
Trial: 12952113
Drug: Omalizumab (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omalizumab (administered every 2 or 4 weeks for 52 weeks)
Trial: 12952113
Drug: Placebo (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered for 28 weeks)
Trial: 10543320
Drug: Hydroxyurea plus
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea plus didanosine (ddI) at a dosage of 500 mg twice a day for at least 40 weeks
Trial: 7776857
Drug: Interferon‐a2b subcutaneously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon‐a2b subcutaneously three times weekly for 12 months (5 MU/m2 for 4 months and then 3 MU/m2 for a further 8 months)
Trial: 7472292
Drug: Anorexigenic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anorexigenic drugs (phenmetrazine)
Trial: 7472292
Drug: Anorexigenic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anorexigenic drugs (phentermine)
Trial: 7472292
Drug: Anorexigenic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anorexigenic drugs (mazindol)
Trial: 30249203
Drug: Self-management (includes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-management (includes educational components, SMBP, and self-titration of antihypertensive medication)
Trial: 27481309
Drug: Brodalumab 350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brodalumab 350 mg
Trial: 27481309
Drug: Brodalumab 700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brodalumab 700 mg
Trial: 26769445
Drug: Enhanced Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced Cognitive Behavioural Therapy (CBT‐E)
Trial: 26769445
Drug: Maudsley Anorexia
RxNorm normalized name: phendimetrazine tartrate Extended Release Oral Capsule [Anorex]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maudsley Anorexia Nervosa Treatment for Adults (MANTRA)
Trial: 23846733
Drug: Metformin (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1,000 mg twice daily for 16 weeks)
Trial: 21120259
Drug: Topical keratolytic
RxNorm normalized name: KERATOLYTICS/CAUSTICS,TOPICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical keratolytic treatment
Trial: 15963095
Drug: Fluvoxamine, 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine, 25 mg twice daily for 6 days
Trial: 1834765
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose Lorazepam (LOR)
Trial: 1834765
Drug: Neither drug
RxNorm normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neither drug (LOR or SCOP)
Trial: 17584562
Drug: Nebivolol 5
RxNorm normalized name: nebivolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol 5 mg (medium dose)
Trial: 17584562
Drug: Nebivolol low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol low dose (1.25 or 2.5 mg)
Trial: 15464768
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose oxytocin (4.5 microm/min initially, increased by 4.5 microm/min every 30 min)
Trial: 15464768
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose oxytocin (1.5 microm/min initially, increased by 1.5 microm/min every 30 min)
Trial: 11374116
Drug: Creatine (Cr)
DrugBank: Creatine (DB00148)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Creatine (Cr) supplementation (5 g of Cr and 5 g maltodextrin four times a day for 5 days)
Trial: 11374116
Drug: Placebo (P)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (P) supplementation (5 g of maltodextrin four times a day for 5 days)
Trial: 7863015
Drug: Moderate and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate and high doses of alcohol
Trial: 7863015
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of diazepam
Trial: 7863015
Drug: Baseline and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline and treatment conditions
Trial: 949688
Drug: Oral methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral methotrexate plus radiation
Trial: 949688
Drug: Intravenous methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous methotrexate plus radiation
Trial: 30382188
Drug: Baclofen (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen (30 mg/d)
Trial: 31079155
Drug: Bioabsorbable polymer
RxNorm normalized name: dicresulene polymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioabsorbable polymer drug-eluting stents (BP-DES)
Trial: 25310347
Drug: Topical dexamethasone
RxNorm normalized name: dexamethasone Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical dexamethasone 0.1%/povidone‐iodine 0.4% eye drops four times daily for seven days
Trial: 25310347
Drug: Artificial tears
RxNorm normalized name: Artificial Tears
DrugBank: Polyethylene glycol 400 (DB11077)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artificial tears four times daily for seven days
Trial: 25310347
Drug: Topical dexamethasone
RxNorm normalized name: dexamethasone Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical dexamethasone 0.1%/povidone‐iodine 0.4% eye drops
Trial: 21565956
Drug: Free oral
RxNorm normalized name: CariFree Oral Paste Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free oral hydration (Group A)
Trial: 21565956
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of 10 mg of furosemide and infusion of 500 mL of saline solution starting 5 min after tracer injection (Group B)
Trial: 21565956
Drug: Oral hydration
RxNorm normalized name: terpin hydrate Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hydration with 500 mL of water (Group C)
Trial: 21565956
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of 10 mg of furosemide and infusion of 250 mL of saline solution starting 30 min after (18)F‐FDG injection (Group D)
Trial: 18651888
Drug: 2% xylocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% xylocaine gel
Trial: 12830441
Drug: Conventional thrice-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional thrice-weekly HD (Control)
Trial: 11296178
Drug: Levofloxacin 500
RxNorm normalized name: levofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500 mg once daily for five doses
Trial: 11296178
Drug: Levofloxacin 750
RxNorm normalized name: levofloxacin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 750 mg once daily for five doses
Trial: 11296178
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg q12h for nine doses
Trial: 8779455
Drug: Piperacillin, 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin, 4 g, given intravenously approximately 30 minutes before ERCP
Trial: 20525705
Drug: torasemide 5
RxNorm normalized name: Torasemide 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: torasemide 5 mg daily
Trial: 16238799
Drug: Standardized unmodified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized unmodified extract (Group A), maximum concentration of 308.5 mcg/mL, 11 injections total.
Trial: 16238799
Drug: Standardized modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized modified allergen extract (Group B), maximum concentration of 2400 mcg/mL, 11 injections total.
Trial: 7892535
Drug: 10 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml/kg of Ringer solution (low dose crystalloid group)
Trial: 7892535
Drug: 20 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml/kg of Ringer solution (high dose crystalloid group)
Trial: 7892535
Drug: 10 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml/kg of Ringer solution with 10 ml/kg of hydroxi‐ethyl‐almidon solution (group C‐HEA)
Trial: 582393
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg viloxazin
Trial: 6896312
Drug: Coke (360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coke (360 ml)
Trial: 6896312
Drug: Tab (360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tab (360 ml)
Trial: 6896312
Drug: Instant Maxwell
RxNorm normalized name: Advanced Eye Relief Redness Instant Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instant Maxwell House coffee (4.5 g)
Trial: 6896312
Drug: Instant Kava
RxNorm normalized name: KAVA
DrugBank: Kava (DB01322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instant Kava coffee (4.5 g)
Trial: 6896312
Drug: Instant Sanka
RxNorm normalized name: Advanced Eye Relief Redness Instant Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instant Sanka coffee (4.5 g)
Trial: 6896312
Drug: Tea (4.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tea (4.25 g)
Trial: 6896312
Drug: Beer (360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beer (360 ml)
Trial: 6896312
Drug: Milk (360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk (360 ml)
Trial: 30792154
Drug: Metformin (pooled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (pooled analysis)
Trial: 30565556
Drug: Group 'A'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 'A' (discontinued treatment)
Trial: 30565556
Drug: Group 'NA'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 'NA' (completed treatment)
Trial: 22232305
Drug: Oral sucrose
RxNorm normalized name: TootSweet 24% Oral Sucrose Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sucrose (0.2 mL/kg)
Trial: 22232305
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of FT and sucrose
Trial: 21125792
Drug: Shuanghuangbu-scaffold extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shuanghuangbu-scaffold extract at 100 microg x mL(-1)
Trial: 7714108
Drug: IL-1 receptor
RxNorm normalized name: IL-1 TRAP
DrugBank: Rilonacept (DB06372)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IL-1 receptor antagonist (IL-1ra) alone (133 mg/h)
Trial: 26319082
Drug: Mammaplasty group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mammaplasty group (MG)
Trial: 19106252
Drug: Standardized functional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized functional physical and occupational therapies for 6 months (PT/OT group)
Trial: 19106252
Drug: Standardized functional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized functional physical and occupational therapies for 6 months plus multimuscle BTX‐A (BTX+ group)
Trial: 9084574
Drug: meloxicam 7.5
RxNorm normalized name: meloxicam 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: meloxicam 7.5 mg per day for 6 days
Trial: 9084574
Drug: indomethacin 25
RxNorm normalized name: indomethacin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: indomethacin 25 mg three times per day for 3 days
Trial: 3490684
Drug: Norfloxacin 400
RxNorm normalized name: norfloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin 400 mg twice daily for 4 to 6 weeks
Trial: 3490684
Drug: Co-trimoxazole 160/800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimoxazole 160/800 mg twice daily for 4 to 6 weeks
Trial: 23061785
Drug: Low-dose ketamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ketamine (loading dose 0.25 mg·kg(‐1), infusion 10-20 μg·kg(‐1)·min(‐1))
Trial: 23061785
Drug: Midazolam (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (loading dose 0.02 mg·kg(‐1), infusion 1-2 μg·kg(‐1)·min(‐1))
Trial: 17058231
Drug: Gabapentin (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (starting dose of 300 mg orally per day, max 2,400 mg)
Trial: 12629464
Drug: HMBCr (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMBCr (3 g/d HMB + 3 g/d Cr)
Trial: 8680887
Drug: Aerosolized pentamidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized pentamidine (AP) 60 mg every 2 weeks
Trial: 8680887
Drug: Aerosolized pentamidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized pentamidine (AP) 120 mg every 4 weeks
Trial: 6344677
Drug: Dihydroergotamine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroergotamine and heparin (0.5 mg dihydroergotamine plus 5,000 units of heparin administered twice daily)
Trial: 6344677
Drug: Heparin (5,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (5,000 units administered three times daily)
Trial: 22682335
Drug: Leucodepleted buffy-coat
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leucodepleted buffy-coat platelet pools prepared in additive solution
Trial: 18069511
Drug: 14% hydrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14% hydrogen peroxide whitening strips used for 30 minutes twice daily for 14 days
Trial: 10468703
Drug: Ranitidine (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (both doses)
Trial: 7604669
Drug: Rectal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal saline infusion test
Trial: 7604669
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of routine anal manometry, rectal saline infusion test, and balloon-retaining test
Trial: 7604669
Drug: Balloon-retaining test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balloon-retaining test vs. rectal saline infusion test
Trial: 18375082
Drug: Diazepam (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (mean dose 12.7 mg)
Trial: 18375082
Drug: Midazolam (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (mean dose 3.9 mg) and Fentanyl (mean dose 108 mcg)
Trial: 1424420
Drug: Zidovudine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine (200 mg every 4 hours while awake) and naproxen (500 mg every 12 hours for 4 days)
Trial: 1424420
Drug: Zidovudine alone
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine alone (200 mg every 4 hours while awake)
Trial: 2869950
Drug: Cholinergic agonists
RxNorm normalized name: PARASYMPATHOMIMETICS (CHOLINERGICS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholinergic agonists
Trial: 31526169
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g aminocaproic acid in 200 mL saline
Trial: 31526169
Drug: 200 mL
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mL normal saline
Trial: 20571249
Drug: pre-treatment with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pre-treatment with tissue-type plasminogen activator (t-PA) combined with back-up of facilitated PCI
Trial: 15618381
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of radiography and MR imaging
Trial: 8636522
Drug: Intratracheal, humidified,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratracheal, humidified, O2‐mixture insufflation (TGI) at 3 l/min
Trial: 8636522
Drug: Intratracheal, humidified,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratracheal, humidified, O2‐mixture insufflation (TGI) at 6 l/min
Trial: 2192529
Drug: Antihypertensive medication
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive medication for 3 months
Trial: 26066385
Drug: Subfascial injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subfascial injection of local anesthetic (Gp SF)
Trial: 26066385
Drug: Extrafascial injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extrafascial injection of local anesthetic (Gp EF)
Trial: 20031771
Drug: Stenting of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stenting of the main branch (MB, Taxus‐stent, paclitaxel‐eluting stents) and mandatory side branch (SB) PCI (kissing balloons) with provisional SB stenting (therapy A)
Trial: 20031771
Drug: Stenting of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stenting of the MB (paclitaxel‐eluting stents) with provisional SB-PCI only when SB had TIMI flow <2 (therapy B)
Trial: 18036082
Drug: Prolonged-release melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged-release melatonin 2 mg (PR-melatonin)